Development of new strategies of human antitumor dendritic cell vaccines

Información del proyecto

MYRTO-GEORDIA TRAKAT

Identificador del acuerdo de subvención: QLK2-CT-1999-51390

Proyecto cerrado

Fecha de inicio 1 Agosto 2000

Fecha de finalización 31 Julio 2002

Financiado con arreglo a

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Coste total € 159 400,00

Aportación de la UE € 159 400,00

Coordinado por

UNIVERSITE LIBRE DE BRUXELLES
Belgium

Objetivo

The project aims to investigate in healthy donors and in melanoma patients, strategies that could improve the generation of MAGE-specific antitumor cytotoxic immune responses by vaccination with autologous dendritic cells.

Ámbito científico

• medical and health sciences › clinical medicine › oncology › skin cancer › melanoma
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines

Programa(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Tema(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Convocatoria de propuestas

Data not available

Régimen de financiación

RGI - Research grants (individual fellowships)

Coordinador

UNIVERSITE LIBRE DE BRUXELLES

• Aportación de la UE: Sin datos
• Dirección: Route de Lennik 808 ; 1070 BRUXELLES ; Bélgica
• Coste total: Sin datos